The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE).
Arnoud J. Templeton
No relevant relationships to disclose
Francisco Emilio Vera-Badillo
No relevant relationships to disclose
Florence Mercier
Consultant or Advisory Role - Sanofi
Guru Sonpavde
No relevant relationships to disclose
Eitan Amir
No relevant relationships to disclose
Bertrand F. Tombal
No relevant relationships to disclose
Mark Rosenthal
Consultant or Advisory Role - Sanofi
Ian Tannock
Research Funding - Sanofi